



PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/659,782
Filing Date	September 11, 2003
First Named Inventor	Liat Mintz
Art Unit	1636
Examiner Name	J. Dunston
Attorney Docket Number	28238

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
JD		US- 6,838,438	01-04-2005	ZymoGenetics, Inc.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ⁴ * Number ⁴ * Kind Code ⁴ (if known)				

Examiner Signature	<i>Jessam Dunston</i>	Date Considered	3/30/2006
-----------------------	-----------------------	--------------------	-----------

*EXAMINER: Initials in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/659,782
		Filing Date	September 11, 2003
		First Named Inventor	Liat Mintz
		Art Unit	1636
		Examiner Name	J. Dunston
Sheet	2	of	3
		Attorney Docket Number	28238

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JD		A. ASAKAWA, et al., Antagonism of ghrelin receptor reduces food intake and body weight gain in mice, Gut 2003;52:947-952	
JD		MARIA A. BEDNAREK et al., Function Studies on the New Growth Hormone-Releasing Peptide, Ghrelin..., J. Med. Chem., 2000, 43, 4370-4376	
JD		MASAYASU KOJIMA et al., Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature, Vol 402, Dec 9, 1999, pp 656-660	
JD		HIROSHI HOSODA et al., Purification and Characterization of Rat des-Gln14-Ghrelin..., J. Biol. Chem., Vol. 275, No. 29, Issue of July 21, pp 21995-2200, 2000	
JD		MITSUYO SHINTANI et al., Ghrelin, and Endogenous Growth Hormone Secretagogue..., Diabetes, Vol. 50, Feb 2001, pp 227-232	
JD		P L JEFFERY et al., Expression and action of the growth hormone releasing peptide ghrelin..., Journal of Endocrinology (2002) 172, Feb 8, 2002, pp R7-R11	
JD		MINORU TANAKA et al., Testis-specific and developmentally induced expression of a ghrelin..., Biochimica et Biophysica Acta, 1522 (2001) pp 62-65	
JD		L. TRUDEL et al., Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus..., Am J Physiol Gastro Liver Physiol 282: G948-G952, 2002	
JD		ANKE HINNEY et al., Ghrelin gene: Identification of missense variants and a frameshift mutation..., J of Clinical Endocrinology & Metabolism 87(6): 2716-2719 (2002)	
JD		MARTA KORBONITS et al., A variation in the ghrelin gene increases weight and decreases..., J of Clinical Endocrinology & Metabolism 87(8): 4005-4008 (2002)	

Duplicate
Cited

Examiner Signature		Date Considered	3/30/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/659,782
Filing Date	September 11, 2003
First Named Inventor	Liat Mintz
Art Unit	1636
Examiner Name	J. Dunston
Attorney Docket Number	28238

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JD		OLAVI UKKOLA et al., Role of Ghrelin Polymorphisms in Obesity Based on Three Different Studies, Obesity Research Vol. 10 No. 8 August 2002 pp 782-791	
JD		ANTONIO TORSELLO et al., Short Ghrelin Peptides Neither Displace Ghrelin Binding In Vitro..., Endocrinology 143(5):1968-1971 (2002)	
JD		DAVID E. CUMMINGS et al., A Preprandial Rise in Plasma Ghrelin Levels Suggests..., Diabetes, Vol. 50, pp 1714-1719, August 2001	
JD		KAZUHIRO KAWAMURA et al., Ghrelin Inhibits the Development of Mouse Preimplantation..., Endocrinology 144(6):2623-2633 (2003)	
JD		A.M. WREN et al., The Novel Hypothalamic Peptide Ghrelin Stimulates Food Intake..., Endocrinology Vol. 141, No. 11, pp 4325-4328 (2000)	

Examiner Signature	<i>J. Dunston</i>	Date Considered	3/20/2006
--------------------	-------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.